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Abstract 
The New Zealand Government has indicated a strong interest in fostering innovation 
and aims to concentrate on selected areas where New Zealand may be able to develop 
a new comparative advantage. One such area is biotechnology, which would build on 
New Zealand’s existing comparative advantage in the primary sector (dairy, forestry, 
meat, wool and horticulture). This paper aims to fill some of the gaps in our 
knowledge of biotechnology and innovation processes in New Zealand. It is based on 
the 1998/99 survey of modern biotechnology activity in New Zealand conducted by 
Statistics New Zealand in 2000. The survey was commissioned by the Ministry of 
Research, Science and Technology (MORST) mainly in order to produce statistics on 
the present position of the industry for planning purposes. The findings reported in 
this paper are based on further analysis of the survey data conducted by the author on 
behalf of MORST. Data are presented on the number, type and characteristics of 
enterprises involved in biotechnology in New Zealand. The paper presents data on 
enterprises that conduct R&D into modern biotech processes and includes analysis of 
the rate of innovation by biotech respondents compared to OECD estimates. 
Comparisons are also made between data from the New Zealand and Canadian 
biotech surveys.  
 
 
Keywords 
biotechnology;  innovation,  New Zealand;  patents;  intellectual property 
 
 
 
JEL Classification 
L65, L66, O31, O32, O38 
 
 
Acknowledgements 
Access to the data used in this study was provided by Statistics New Zealand under conditions 
designed to give effect to the security and confidentiality provisions of the Statistics Act 
1975. Standard Statistics’ random rounding to base three has been applied to all output. 
Disclaimer 
The results presented in this study are the work of the author not Statistics New Zealand. 
Modern Biotechnology In New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99 
 
Department of Economics, University of Waikato  
 
i
Contents 
Key Indicators of Biotech Activity in New Zealand................................................. ii 
Executive Summary ................................................................................................... iii 
1. Introduction ..........................................................................................................1 
1.1 Background ....................................................................................................1 
1.2 What is Biotechnology?..................................................................................2 
1.3 Meaning of Biotech Terms Used in this Report .............................................4 
2. Modern Biotech R&D and Use in New Zealand................................................7 
2.1 Enterprises Involved.......................................................................................7 
2.2 Biotech Processes.........................................................................................10 
2.3 Product and Process Development ..............................................................14 
3. Characteristics of the Biotechnology ‘Industry’ .............................................17 
3.1 Industry Sectors............................................................................................17 
3.2 Strategic Alliances........................................................................................18 
3.3 Intellectual Property Rights .........................................................................21 
3.4 Income, Expenditure and Exports ................................................................23 
3.5 Human Resources.........................................................................................25 
3.6 Problems Affecting Biotech R&D ................................................................26 
4. International Comparisons................................................................................27 
5. Modern Biotech Enterprises in New Zealand..................................................29 
5.1 Introduction..................................................................................................29 
5.2 Enterprises Involved.....................................................................................29 
5.3 Biotech Processes.........................................................................................29 
5.4  Product and Process Development ..............................................................29 
5.5  Industry Sectors............................................................................................30 
5.6  Strategic Alliances........................................................................................30 
5.7 Intellectual Property Rights .........................................................................30 
5.8 Income, Expenditure and Exports ................................................................30 
5.9 Human Resources.........................................................................................31 
5.10 Problems Affecting Biotech R&D ................................................................31 
Appendix Tables.........................................................................................................32 
References ...................................................................................................................42 
Modern Biotechnology In New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99 
 
Department of Economics, University of Waikato  
 
ii
Key Indicators of Biotech Activity in New Zealand 
 
 Modern 
Biotech 
Enterprises 
Traditional 
Biotech 
Enterprises 
Modern 
Biotech 
Users 
Traditional 
Biotech 
Users 
All  
Biotech 
Respondents 
No. of Respondents and Processes      
No. of Respondents 57 24 36 63 180 
No. in Private Sector 30 21 21 30 102 
Biotech Processes per enterprise 19 3 8 4 9 
No. Involved in DNA Based Processes 42 0 9 0 51 
Innovation Indicators      
No. New Products last 3 yrs 114 18 27 18 180 
No. New Processes last 3 yrs 105 21 45 9 177 
% Introducing New Product or Process 68% 50% 42% 24% 45% 
New Products & Processes per Enterprise 3.8 1.8 2.0 0.4 2.0 
No. Processes New to the World last 3 yrs 30 6 3 0 39 
No. New Products Planned Next 3 years 207 24 42 21 298 
No. New Processes Planned Next 3 years 219 12 24 30 288 
New Products & Processes per Enterprise 7.5 1.5 1.8 0.8 3.3 
No. of Patents Applications Last 5 Yrs 147 6 3 0 156 
Patents Applications per Enterprise 2.6 0.3 0.1 0 0.9 
Biotech Income and Exports      
Total Income ($ million) 2,124 1,008 1,647 2,475 7,254 
Biotech Income ($ million) 236 68 112 59 475 
Biotech as % of Total Income 11% 7% 7% 2% 7% 
Biotech Income per Enterprise ($ million) 4.1 2.8 3.1 0.9 2.6 
Biotech Exports 60 c1 40 c 170 
Biotech Employment      
Full-time Equivalents (yr to 30 June ‘99) 1,667 c c 155 2,984 
PhDs 667 c c c 703 
Graduates 1,512 c c c 1,824 
Graduates per Enterprise 27 c c c 10 
Biotech Alliances      
% Reporting Biotech Alliances 90% 50% 42% 24% 53% 
% Reporting Alliance with CRI 68% 25% 17% 14% 32% 
% Reporting Alliance with Business 47% 13% 17% 10% 22% 
                                                 
1 c indicates cell ‘confidentialised’ to give effect to the confidentiality provisions of the Statistics Act 
1975 
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Executive Summary 
 
Background 
Over the last few years there has been an explosion of interest in Biotechnology in 
New Zealand. Politicians and policy makers have become increasingly interested in 
the role that biotech might play in the ‘new economy’; and aware of the policy 
initiatives in support of biotech which have been implemented by many of our 
competitors. In 1999 the Ministry of Research Science and Technology (MORST) 
commissioned Statistics New Zealand to undertake a survey to investigate the use of 
biotechnology in New Zealand. The survey was intended to focus on modern 
biotechnology because of its perceived importance for New Zealand’s future 
economic development. The 1998/99 survey of modern biotechnology activity in New 
Zealand was conducted by Statistics New Zealand in 2000 with the results being 
published in April 2001. The findings reported in this document are based on further 
analysis of the survey data conducted by the author on behalf of the Ministry of 
Research, Science and Technology. 
 
This report adopts a rule based definition modern biotechnology as: (1) recombinant 
DNA technology, (2) use of antibodies (3) protein engineering (4) novel 
bioprocessing techniques (Eliasson & Eliasson, 1997, p. 145; U.S. Congress, 1991, p. 
5). The term “modern” is used to distinguish processes that have been developed in 
the last 30 years or so, from traditional biotech areas such as fermentation and 
extraction. 
 
A further distinction has been drawn based on whether respondents used modern or 
traditional processes and whether they conducted R&D (creators) or were simply 
users of biotechnology processes. These characteristics have been used to define four 
categories of biotech respondents; those engaged in R&D (or not) and those using 
modern vs. traditional biotech processes. The term Modern Biotech Enterprise (MBE) 
is used to describe respondents that are engaged in R&D into at least one modern 
biotech process. Academics and policy makers have a particular interest in this group, 
since their innovative performance will be crucial in determining New Zealand’s 
overall performance in the biotech area. 
 
Enterprises Involved 
Questionnaires were sent to 426 enterprises that had been identified as possible users 
of modern biotechnology processes. The survey achieved a 98% response rate with 
180 enterprises being identified as users of at least one biotechnology process. The 
high response rate and wide ranging processes used to identify possible users of 
modern biotechnology suggest that the survey is likely to have captured almost all 
significant users of modern biotech in New Zealand over the survey period (1998/99). 
 
93 enterprises used modern biotechnology; 57 of these were also engaged in R&D and 
so were defined as Modern Biotechnology Enterprises. 
 
The survey also included enterprises that use traditional biotech processes. 87 survey 
respondents used traditional biotech processes; 24 of these were also engaged in R&D 
and so were defined as Traditional Biotech Enterprises. 
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Estimates on the size of the traditional biotech ‘sector’ cannot be regarded as being 
complete since a significant numbers of other users of such processes were not 
included in the survey, or reported that they did not use modern biotech and so did not 
fill in the questionnaire.  
 
● 57 Modern Biotech Enterprises (MBEs) were spread across various industrial 
groups particularly scientific research organisations (24) primary product and 
manufacturing enterprises (15) and Universities (6). They included 42 
enterprises which develop and use DNA based processes and 24 which develop 
and use genetic engineering.  
● 36 Modern Biotech Users (MBU) were spread across most industrial groups 
with the largest number being hospitals and health providers, around three 
members of this group also research traditional biotech processes;  
● 24 Traditional Biotech Enterprises (TBEs) were concentrated in the food and 
non-food manufacturing groups; 
● 63 Traditional Biotech Users (TBU) include local authorities that use biotech 
for sewage treatment and food and non-food manufacturers including brewers of 
wine and beer, bakers etc. 
 
Biotech Processes 
Biotech respondents reported use of 1647 processes; universities had by far the most 
diverse involvement reporting an average of 33 different biotech processes per 
institution. They were followed by research organisations (including CRIs) with an 
average of 14 processes per organisation. Modern Biotech Enterprises reported use of 
1060 processes – an average of 19 processes per enterprise – compared to 5 per 
enterprise for biotech users. The survey included 246 respondents that did not use a 
biotech process in 1998/99; none of these said that they planned to start using specific 
processes within three years, although three indicated possible use at some stage. 
 
Use of modern biotech in New Zealand is at an early stage of development with many 
enterprises being involved primarily in R&D. Overall slightly over half (53%) of 
biotech respondents reported use of at least one biotech process for R&D or process 
development. 85% reported use of biotech processes as ‘part of the production 
process’, while 45% used at least one process ‘as part of product sold’. 
 
51 different enterprises were involved in DNA based processes, 81 in environmental 
processes and 132 and 156 in biochemical and bioprocessing based processes 
respectively. 
 
24 enterprises reported use of genetic engineering (GE) or recombinant DNA, most of 
these being research institutions and universities. 21 used GE for R&D, 6 used it as 
part of the ‘production process’ while 3 used it in ‘production sold’. 
 
Product and Process Development 
33% of respondents reported implementation of a new biotech product over the last 
three years, with the innovation rate being lowest for local government (9%) and food 
manufacturers (27%), around 50% for four other industrial groups and 33% for 
tertiary organisations. Process innovation rates were fairly similar. 
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42% of enterprises indicated that they were planning to implement a total of 298 new 
products in the next 3 years, this compares with 180 in the last 3 years. Similarly 40% 
of enterprises reported plans to implement a total of 288 new processes (compared to 
177 in the last 3 years). This suggests a significant increase in the rate of new product 
and process development.  
Modern biotechnology enterprises (MBEs) were far more active than other groups in 
new product and process development. MBEs introduced a total of 219 new products 
and processes over the last 3 years (an average of 3.8 per enterprise).  
 
Further work is required before definite conclusions can be reached on the relative 
innovative output of New Zealand biotech firms relative to similar firms in other 
countries. The evidence reviewed in this report does not support the idea that New 
Zealand biotech firms have a particularly high rate of new product or process 
development.  
 
Industry Sector 
Modern Biotech Enterprises were most involved in the ag-bio and human health 
sectors, followed by food processing, genomics/molecular modelling, aquaculture and 
the environment. The environment industry sector was reported most frequently by 
Traditional Biotech Users –  reflecting  the waste treatment activities of  local 
authorities. Modern Biotech Users most reported sector was human health – reflecting 
the activities of health services respondents. 
 
Strategic Alliances 
52% of biotech respondents reported a partnership/alliance with a total of 303 
different organisation types; this suggests that the 93 respondents that had alliances 
had an average of at least three partners each. 90% of MBEs reported alliances. 
The proportion of respondents reporting an alliance varied markedly between industry 
groups from 100% in tertiary education to a low of 18% for local government. Overall 
47% reported at least one New Zealand alliance while 31% reported an overseas 
alliance. Overseas alliances were most common in the tertiary education, non-food 
manufacturing and scientific research groups. 
 
● The most commonly reported alliance purposes were product/process 
development – reported by 81% of respondents who had an alliance and 
clinical/field trials (48%).  
● 32% of respondents reported alliances with CRIs, followed by universities 
(27%) and other businesses (22%).  
● 68% of MBEs reported alliances with CRI’s and 47% reported biotech alliances 
with other businesses.  
 
Intellectual Property Rights 
25% of respondents reported at least one IP related problem. Positive responses were 
concentrated in the MBE category where 47% reported at least one problem - IP 
rights were clearly a significant problem for this group. 
 
Only a small proportion of biotech respondents had made any patent applications. In 
the previous five years, 33 enterprises (18% of respondents) had made a total of 156 
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successful biotech patent applications (147 by MBEs). Nine respondents were 
responsible for 70% of all biotech patent applications. 
 
Conference and Publishing Activity 
At least one member of staff from 70% of respondents had attended a national or 
international conference ‘on a biotechnology subject’. Staff from 22% of respondents 
had published an article on biotechnology in a refereed journal.  
 
MBEs had a markedly higher rate of conference and publishing activity: 95% of 
respondents had been involved in a biotech conference and staff from 58% had 
published a refereed journal article. 
 
Income, Expenditure and Exports 
Survey respondents estimated that income of $475 million was attributable to modern 
biotechnology, in the year ended June 1999 - $326 million from private sector 
respondents, $149 million from the public sector. This compares to respondents 
income from all sources of $7.25 billion i.e overall biotech provided around 7% of 
income for the 180 biotech using enterprises.  
 
Biotech respondents reported total exports of $1.75 billion and biotech exports of the 
order of $170 million. 42% of biotech respondents reported exports, while biotech 
exports were reported by 23%. 
 
MBEs estimated that income of $236 million was attributable to modern 
biotechnology, in the year ended June 1999 - $122 million from private sector 
respondents, $115 million from the public sector. MBEs reported total exports of 
$300 million and biotech exports of the order of $60 million.  
 
Human Resources 
Survey respondents reported that a total of 3057 (or 2984 full time equivalent) staff 
supported biotech activity. Around 67% were graduates and 26% had PhD’s.  
 
MBEs employed 1667 biotech staff (FTE) – 56% of the total for all respondents. 
Employment of qualified staff was heavily concentrated in MBEs; they employed 
83% of biotech graduates and 95% of PhDs. 
 
Problems Affecting Biotech R&D 
Around 59% of respondents reported at least one problem affecting biotech R&D 
(most of the remainder did not report any R&D activity); 89% of MBEs reported at 
least one problem. The problems reported most frequently by all respondents were 
access to capital and regulations.  
 
International Comparisons 
The Statistics New Zealand biotech survey was closely modelled on work carried out 
by Statistics Canada thus enabling some comparisons to be made. New Zealand’s 
biotech revenue per million population (NZ$54 million) is rather lower than Canada's 
(NZ$94 million). New Zealand has a rather lower mean revenue per biotech firm 
($5.3m vs $8.0m); consistent with the predominance of SMEs in the New Zealand 
economy. New Zealand appears to have a significantly higher rate of biotech 
employment. 
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1. Introduction 
1.1 Background 
Over the last few years there has been an explosion of interest in Biotechnology in 
New Zealand. Politicians and policy makers have become increasingly interested in 
the role that biotech might play in the ‘new economy’; and aware of the policy 
initiatives in support of biotech which have been implemented by many of our 
competitors. The biotech industry has begun to achieve critical mass and has been 
increasingly effective in lobbying for policy changes that would make the New 
Zealand environment more supportive of biotech R&D and innovation. At the same 
time, increasing levels of popular concern over the safety of some modern 
biotechnologies culminated in the setting up of the Royal Commission on Genetic 
Modification that spent over $6 million and 14 months listening to all sides of the 
debate. In October 2001 the government announced its response to the Royal 
Commission report, including permission for field trials to restart and a two-year ban 
on commercial release of genetically modified products. These factors have combined 
to ensure that there is a high level of interest in data and analysis on development and 
use of modern biotechnologies in New Zealand. 
 
In 1999 the Ministry of Research Science and Technology (MORST) commissioned 
Statistics New Zealand to investigate the use of biotechnology in New Zealand. The 
main purpose was to “produce statistics concerning the present position of this 
industry in New Zealand” in order to “take stock of the current situation for planning 
purposes”(Statistics New Zealand, 2000b, p. 1). The survey was intended to focus 
only on modern biotechnology since it was thought that “the contribution to future 
economic development resulting from modern biotechnology is likely to be much 
greater than the potential contribution by its traditional counterpart”. The objectives2 
of the survey were: 
 
● To understand the present status, the structure and the future progression of the 
biotechnology industry in New Zealand. 
● To assess the present status of strategic alliances, the links with the public / 
private research system and the potential for cluster development for the 
biotechnology industry. 
● To provide a baseline on the utilisation of resources including the knowledge in 
the biotechnology industry against which progress could be compared at a 
future date. 
● To identify the enabling factors and constraints facing the biotechnology 
industry in New Zealand. 
 
The 1998/99 survey of modern biotechnology activity in New Zealand was conducted 
by Statistics New Zealand in 2000 with the results being published in April 20013.  
 
                                                 
2 Source: Ministry of Research, Science and Technology (2000) Draft Objectives for the Biotechnology 
Survey. 
3 Statistics New Zealand. (2001). Modern Biotechnology Activity in New Zealand. Wellington. 
4  Marsh, D. (2001) Modern Biotechnology in New Zealand: Methodological Issues and Analysis of 
Free Text Responses from the Biotechnology Survey 1998/99.  
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Relationship of this Report to ‘Modern Biotechnology Activity in New 
Zealand’  (Statistics New Zealand, 2001) 
This report is based on further analysis of the survey data conducted by the author on 
behalf of the Ministry of Research, Science and Technology. This included preparation of 
additional tables and cross tabulations; presentation and analysis of the data in alternative 
formats; and breakdowns based on four new respondent categories (see Figure 1). Some 
of the results presented here may appear to conflict with those published by Statistics New 
Zealand. This is mainly explained by different treatment of multiple responses from single 
enterprises5. 
 
 
1.2 What is Biotechnology? 
The term biotechnology was coined in 1919 by Karl Ereky, a Hungarian engineer to 
refer to “all the lines of work by which products are produced from raw materials with 
the aid of living organisms”(Bud, 1989, p. 10). Since then “the word biotechnology 
has been re-developed at least four times and its definition changed on each occasion” 
(Kennedy, 1991, p. 218). For much of the twentieth century it has been a broad term 
applied to technologies ranging from the fermentation of products such as wine and 
beer through extraction and sewage treatment to the selective breeding of plants. 
However in recent years the term has become increasingly synonymous with genetic 
modification so for example, the recent Pew report on agricultural biotechnology 
states: 
For the purposes of this report … the term “biotechnology” refers to the use of 
recombinant DNA technology to take genes from one organism and insert them 
into the DNA of another plant or animal. (Pew Initiative on Food and 
Biotechnology, 2001, p.4) 
Modern biotechnology is usually traced back to the development of the recombinant 
DNA technique in 1973 and hybridoma technology in 1975 (Orsenigo, 1989, p. 37). 
Government, business, academic and media interest has tended to focus on modern 
biotechnology because it has the potential to transform large parts of the global 
economy and to have a major impact on the way we live. Indeed the rapid pace and 
widespread impact of developments in biotechnology since the 1970s has often been 
referred to as the biotechnology revolution.  
 
In New Zealand there has been strong resistance to redefinition of biotechnology to 
mean genetic modification. For example, Biotenz (2001, p. 9) suggests that this “will 
seriously undermine the ability of the New Zealand economy and New Zealanders to 
benefit from new knowledge and new technologies in traditional industries”. 
Similarly, the New Zealand Biotechnology Association (NZBA) “represents the 
interests of people with an interest in biotechnology, and the biotechnology industry 
                                                 
5 A number of universities and hospitals returned multiple questionnaires each referring to the activities 
of a different part of the organisation. In many of the report tables Statistics New Zealand treated these 
organisation subunits as equivalent to a separate response from an individual survey respondent. This 
had the effect of increasing the number of responses from ‘biotech using enterprises’ from 180 to 218. 
In the current analysis multiple responses from single organisations have been aggregated in order to 
create the single responses that would have been sent in had such organisations submitted only one 
questionnaire. See also Marsh, D. (2001) Modern Biotechnology in New Zealand: Methodological 
Issues and Analysis of Free Text Responses from the Biotechnology Survey 1998/99. 
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in its broadest sense” and defines biotechnology as “the application of scientific and 
engineering principles to the processing of material by biological agents and the 
processing of biological materials to improve the quality of life6”. NZBA membership 
includes a spectrum of organisations engaged in activities ranging from traditional 
biotechnology through to genetic modification. 
 
The 1998/99 Statistics New Zealand survey adopted a dual approach to the definition 
of biotechnology. The stated purpose was to collect statistics on modern 
biotechnology and the second page of the questionnaire started with the New Zealand 
Biotechnology Association definition7 of modern biotechnology: 
the application of scientific and engineering principles to the processing of 
material by biological agents and the processing of biological materials to 
improve the quality of life by isolating, modifying and synthesising the genetic 
instructions responsible for actual biological processes (Statistics New Zealand, 
2000a, p. 2) 
Respondents were then asked to review a list of biotechnology processes (see Table 1) 
and indicate which if any were used by their business. This was based on a list of 
technologies developed by Statistics Canada. An expert panel also added several 
processes in order to develop a definition appropriate to New Zealand.  
 
While the stated intention of the survey was to focus on modern biotechnology it 
included a fairly wide list of processes, many of which have been around for quite 
some time. As a result many of the enterprises that reported use of biotech processes 
were involved in traditional rather than modern biotechnology. 
 
Table 1: Statistics New Zealand’s List Based Definition of Biotechnology 
 
Main Category Sub Categories 
DNA Based Technology Genetic engineering, Gene Probes, Bio-informatics, Genomics, 
Pharmacogenetics, Gene Therapy, Rational Drug Design, DNA Sequencing, 
Synthesis, Amplification 
Biochemistry or 
Immunochemistry based 
Vaccines, Immune Stimulants, Drug Design and Delivery, Combinatorial 
Chemistry, Diagnostic Tests, Peptide/Protein Synthesis and Sequencing, Cell 
Receptors and Cell Signalling, Bio-Sensing, Pheromones, Molecular 
Modelling, Structural Biology, Antigens, Antibodies, Microbiology, 
Biomaterials 
Bio Processing Cell, Tissue and Embryo Culture, Cell, Tissue and Embryo Manipulation, 
Somatic Embryo genesis, Fermentation, Bio processing, Bio transformation, 
Bio leaching, Bio pulping, Bio bleaching, Bio desulphurisation, Bio pesticide 
Manufacturing, Extraction, concentration, purification, separation, Natural 
Products Chemistry, Bio filtration, Bio indicators, Micro-selected Breeding of 
Plants and Animals, Microbio inoculants, Bio Sensing 
Environmental 
Biotechnology 
Bio augmentation, Bio reactors, Biological Gas Cleaning, Bio remediation, 
Phyto remediation 
Source: Statistics New Zealand (2000a, p. 39) and author’s calculations 
For the purposes of this report, processes in italics are ‘modern’, other processes are ‘traditional’ 
See Table A13 for a more detailed breakdown. 
 
In an attempt to extract more meaning from the survey data, this report adopts specific 
rule based definitions of traditional and modern biotechnology (see below). Our 
                                                 
6 http://www.biotech.org.nz/objectives.htm 
7 This definition appears to be open to alternative interpretations depending on whether the reader 
considers that the specifications before and after the ‘and’ must both be fulfilled. 
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definition of modern biotechnology follows authors such as Eliasson and Eliasson 
(1997, p. 145) who state that: “the biotech field is thought of as consisting of three or 
four sub-areas: (1) recombinant DNA technology, (2) use of antibodies including 
phage display, and (3) protein engineering…” and the U.S. Congress, Office of 
Technology Assessment (1991, p. 5) which defined ‘new’ biotechnology as: “the 
industrial use of rDNA, cell fusion and novel bioprocessing techniques”. It should be 
recognised that any definition of modern biotech will be somewhat arbitrary since 
there is a continuum from the most traditional biotechnologies e.g. fermentation 
through to the most modern e.g. proteomics (see Figure 1). 
  
The list of processes in Table 1 has been divided into ‘modern’ (processes in italics) 
and ‘traditional’ processes with the aim of separating enterprises involved in 
processes that have been developed in the last 30 years or so, from those involved in 
traditional areas e.g. fermentation, extraction etc (see Appendix Table A13 for further 
details). 
 
A further distinction has been drawn between users of biotechnology processes and 
creators who conduct R&D and are active in developing new processes and products8. 
These characteristics have been used to define four categories of biotech respondents; 
modern and traditional biotech enterprises and modern and traditional biotech users 
(defined below). Academics and policy makers have a particular interest in modern 
biotech enterprises (MBEs), since their innovative performance will be crucial in 
determining New Zealand’s overall performance in the biotech area. 
 
1.3 Meaning of Biotech Terms Used in this Report 
 
Biotechnology 
“the application of scientific and engineering principles to the processing of materials 
by biological agents to provide goods and services” (Bull, Holt, & Lilly, 1982) 
This is the definition used by the OECD. 
 
Modern Biotechnology 
For the purposes of this report, modern biotechnology is defined as: (1) recombinant 
DNA technology, (2) use of antibodies (3) protein engineering (4) novel 
bioprocessing techniques (Eliasson & Eliasson, 1997, p. 145; U.S. Congress, 1991, p. 
5). The term “modern” is used to distinguish processes that have been developed in 
the last 30 years or so, from traditional biotech areas such as fermentation and 
extraction. 
 
Biotech Respondent 
● Any enterprise which uses at least one biotech process (as listed in Table 1) 
 
Modern Biotech Enterprise (MBE)  
● Uses at least one modern biotech process (see Table 1); 
● Conducts R&D involving at least one modern biotech process; 
                                                 
8 It may also be useful to think of a continuum in this area ranging from the most creative/innovative 
enterprises through to users that have no innovative or development input. 
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● At least one (FTE) graduate ‘supports biotechnology activity’9; 
● May also be a TBE and/or MBU or TBU (see below). 
 
Figure 1: Classification of Biotech Respondents 
 
 Modern    Traditional 
Modern Biotech 
Enterprises  
(MBEs) 
Traditional Biotech 
Enterprises 
(TBEs) 
Creators 
 
 
 
 
Users 
Modern Biotech 
 Users 
(MBUs) 
Traditional Biotech 
Users 
(TBUs) 
 
Traditional Biotech Enterprise (TBE) 
● Uses at least one traditional biotech process (but no modern processes); 
● Conducts R&D involving at least one biotech process; 
● At least one (FTE) graduate ‘supports biotechnology activity’. 
● May also be a TBU. 
 
Modern Biotech User (MBU) 
● Uses at least one modern biotech process; 
● Does not conducts R&D into modern processes, or does not have at least one 
(FTE) graduate ‘supporting biotechnology activity’; 
● May also be a TBE. 
 
Traditional Biotech User (TBU) 
● Uses at least one traditional biotech process; 
● Does not conducts R&D, or does not have at least one (FTE) graduate 
‘supporting biotechnology activity’. 
                                                 
9 A number of enterprises reported that they conducted R&D into modern biotech processes but had 
less than one FTE graduate working in the biotech area. It is assumed that such R&D must be very 
small scale so these enterprises are defined as biotech users. 
10 A number of enterprises reported that they conducted R&D into modern biotech processes but had 
less than one FTE graduate working in the biotech area. It is assumed that such R&D must be very 
small scale so these enterprises are defined as biotech users. 
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Modern biotechnology is used in a number of different economic sectors ranging from 
food and non-food manufacturing through various primary industries to health, 
diagnostic and environmental applications (see Figure 2). The terms ‘biotech industry’ 
and ‘biotech sector’, although not strictly ‘correct’ may be used to denote the group of 
industries and sectors that use biotechnologies. 
 
Figure 2: Sectors Contributing to the Biotechnology ‘Industry’ 
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2. Modern Biotech R&D and Use in New Zealand 
 
2.1 Enterprises Involved  
Questionnaires were sent out to 426 enterprises that had been identified as possible 
users of modern biotechnology processes. The survey achieved a 98% response rate 
with 180 enterprises being identified as users of at least one biotechnology process. In 
the remainder of this paper these are referred to as ‘biotech(nology) respondents’, 
although it should be noted that this does not necessarily imply that biotechnology is 
their main activity. The high response rate and wide ranging processes used to 
identify possible users of modern biotechnology suggest that the survey is likely to 
have captured almost all significant users of modern biotech in New Zealand over the 
survey period (1998/99). 
 
The survey also included enterprises that use traditional biotech processes (TBU). 
Estimates on the size of the traditional biotech ‘sector’ cannot be regarded as being 
complete since a significant numbers of other users of such processes were not 
included in the survey, or reported that they did not use modern biotech and so did not 
fill in the questionnaire. For example 33 ‘local authority’ enterprises reported use of 
biotech processes – primarily for treatment of sewage and wastewater but around 20 
reported no involvement.  
 
Table 2: Number of Enterprises Involved in Biotechnology, 
by Industrial Grouping 
 
Industrial Group No.  
Enterprises 
Involved in  
Biotech 
Activity 
Total No. 
Enterprises in 
each Industrial 
Group 
No. of  
Biotech 
Processes 
 Used  
No.  
Processes  
per Enterprise 
Primary Products 6  8,122 33 6 
Food Manufacturing  33  1,268 207 6 
Non-Food 
Manufacturing 
24 591 153 
6 
Scientific Research  36  5,404 513 14 
Local Government 
Administration  
33 201 150 5 
Tertiary Education 9  76 297 33 
Health Services  24  3,536 237 10 
Other  12  25,036 57 5 
Total  180 44,234 1,647 9 
Note: Other includes water supply, sewerage and drainage services, veterinary services, parks and 
gardens.  
 
The 180 biotechnology respondents were spread fairly evenly over five main 
industrial groups: food and non-food manufacturers, scientific research, and local 
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government and health services. Overall, fewer than half of one per cent of enterprises 
in the above industrial groupings made any use of biotech. See Table 211 
 
Biotech respondents were concentrated in a small number of industrial groups; 120 of 
the 180 respondents falling under 8 ANZSIC categories (at the 5 digit level), see 
Table 3. A more detailed breakdown by ANZSIC category is included in the 
Appendix as Table A1. 
 
Table 3: Number of Biotech Enterprises in Selected ANZSIC Categories 
 
Dairy Product Manufacturing     6 
Wine Manufacturing      9 
Medicinal and Pharmaceutical Product Manufacturing  15 
Scientific Research      24 
Technical Services nec      6 
Local Government Administration     33 
Higher Education      12 
Hospitals (except psychiatric)    15 
Total No of Respondent in above categories   120 
 
Other ANZSIC Categories     60 
   
 
Figure 3: Institutional Breakdown of Biotech Respondents 
 
Around 60% of biotech respondents were from the private sector (including 
manufacturers, research enterprises and laboratories), the remainder being mainly 
comprised of local and regional authorities, universities, crown research insititutes 
and health providers12 (see Figure 3 and appendix Table A2 for more details).  
Modern biotech enterprises were split fairly evenly between the private sector (30) 
and the public sector (27). 
 
It is also useful to distinguish between enterprises engaged in modern biotech (i.e. 
processes developed in the last 30 years) rather than traditional biotech and between 
users of biotech processes and those which conduct R&D and are active in the 
development of new processes and products (see section 1.3). Around 80 biotech 
                                                 
11 All tables are based on analysis of data from the Biotechnology Survey 1998/99 unless otherwise 
stated. 
12 Formerly known as Crown Health Enterprises 
54%
3%
24%
19%
Private Private Non-Profit
Central Government Local and Regional Government
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respondents conducted R&D; 57 of these conducted R&D into modern processes; 
these are classified as Modern Biotech Enterprises (MBEs). A further 36 respondents 
used modern biotech processes but were not engaged in a significant level of R&D, 
while 63 respondents used traditional processes e.g. fermentation, extraction, 
diagnostic tests etc. and were not engaged in R&D. 
 
● 57 MBEs were spread across various industrial groups particularly scientific 
research organisations (24) primary product and manufacturing enterprises (15) 
and Universities (6). They include 42 enterprises which develop and use DNA 
based processes and 24 which develop and use genetic engineering.  
● 24 Traditional Biotech Enterprises (TBEs) were concentrated in the food and 
non-food manufacturing groups; 
● 36 Modern Biotech Users (MBU) were spread across most industrial groups 
with the largest number being hospitals and health providers, around three 
members of this group also research traditional biotech processes; 
● 63 Traditional Biotech Users (TBU) include local authorities that use biotech 
for sewage treatment and food and non-food manufacturers including brewers of 
wine and beer, bakers etc. 
 
Figure 4: Respondent Category vs Industrial Group 
Note: This figure is based on data in Table A3 
MBEs TBEs
MBEs 16
26
0
7
5 4Primary Products, Food and Non-Food Manufacturing
Scientific Research
Local Government
Tertiary Education
Health Services
Other
MBUs TBUs
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2.2 Biotech Processes 
Respondents were asked to review a list of 54 biotech processes and indicate whether 
“each process was used in operations by this business during the accounting year”. 
They also had the option of recording any other biotech process not included in the 
questionnaire13. Respondents were then asked whether the process was used: 
● in “research & product/process development”; 
● as “part of the production process”; or 
● as “part of the product sold”. 
In the case of processes which were not used, respondents were asked: 
● “does this business plan to use this process in the next three years?”. If they had 
no plan to use they were asked whether this was because “it has no application 
to this business” or “it is not cost effective”14. 
Number of Processes Used 
Biotech respondents reported use of 1647 processes15; universities had by far the most 
diverse involvement reporting an average of 33 different biotech processes per 
institution. They were followed by research organisations (including CRIs) with an 
average of 14 processes per organisation. Local government and private sector 
organisations were involved in far fewer processes – an average of five or six per 
respondent.  
87 respondents used 5 biotech processes or less; they tended to be food or non-food 
manufacturers (36) or local authorities (21); 70% of this group did not carry out 
biotech R&D.  
57 Modern Biotech Enterprises reported use of 1060 processes – an average of 19 
processes per enterprise – compared to 5 per enterprise for biotech users (see Table 4). 
 
Table 4: Frequency Distribution for Number of Biotech Processes Used 
 All 
Biotech 
Respondents 
Modern  
Biotech  
Enterprises 
1  18 
2 24 
3 18 
4 15 
5 12 
6 
6  to 10 48 12 
More than 10 45 39 
 
                                                 
13 A total of 15 ‘other’ processes were recorded by respondents, many of these are not considered to be 
modern biotech, other responses will assist with improved process definitions in future surveys.  
14 Most respondents reported that processes that they did not use ‘had no application to this business’. 8 
processes were reported not cost effective by 9 respondents, 19 by 6 respondents, 23 by 3 respondents, 
8 by 0 respondents (see Table A4). No clear pattern could be discerned as to which processes were 
reported to be not cost effective vs. not applicable. 
15 This is the sum of the number of processes used by each organisation. This number is different to 
that reported by SNZ for reasons discussed under methodology (in the supporting report). 
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Figure 5 and Table A4 record the number of respondents reporting use of each biotech 
process (broken down by stage of use). The most frequently used processes were 
microbiology16 (105 respondents), cell culture (69), bioindicators (69) and diagnostic 
tests (66). Several of these processes were defined in fairly general terms, none are 
specific to modern biotechnology. Several processes were used by very small 
numbers of enterprises (less than 8), namely gene therapy, pharmacogenetics, 
biopulping, biobleaching, bioleaching and biodesulphurisation. 
Stage of Use 
Use of modern biotech in New Zealand is at an early stage of development with many 
enterprises being involved primarily in R&D. Overall slightly over half (53%) of 
biotech respondents used at least one biotech process for R&D or process 
development (Table 5). 85% reported use of biotech processes as ‘part of the 
production process’, while 45% used at least one process ‘as part of product sold17’. 
There is significant variation between the different biotech areas, for example: 
 
● 76% of enterprises using DNA based processes conducted R&D in this area 
while only 24% used these processes as ‘part of product sold’ 
● Results for enterprises using biochemistry and bioprocessing are fairly similar – 
around 55% conducted R&D in these areas, 68/77% used processes as part of 
the production process and around 40% used processes as ‘part of the product 
sold. 
● Enterprises using environmental biotech processes were least likely to conduct 
R&D in this area (37%) and most likely to use these processes as ‘part of the 
production process’ (particularly use of bio-reactors and bioaugmentation for 
sewage treatment).  
 
Table 5: Percentage of Enterprises Involved in Different Biotech Areas by Stage 
 
Biotech Area No. of 
Enterprises 
Involved at 
any stage 
% Using 
Processes in 
R&D/ 
Process 
Development
% Using 
Processes as 
‘Part of the  
Production 
Process’ 
% Using 
Processes as 
‘Part of 
Product Sold 
No. Planning 
to Use in 
next 3 years
(not using 
now) 
DNA Based Processes 51 76% 35% 24% 9 
Biochemistry Based 132 57% 68% 43% 3 
Environmental Biotech 81 37% 78% 19% 9 
Bioprocessing Based 156 54% 77% 37% 3 
Enterprises Involved 
in each Stage 180 53% 85% 45%  
Note: Percentages are expressed as a proportion of the number of enterprises involved in each area 
e.g. ‘76% of the 51 firms that used DNA based processes used DNA based processes for R&D’. 
Enterprises may use the same process in more than one stage. 
 
                                                 
16 The definition of each of these terms is provided in the Statistics New Zealand (2000a) questionnaire. 
17 This apparently contradictory statement is derived directly from the questionnaire. It is used because 
an enterprise might report, for example, that genetic engineering is researched, is part of the production 
process or is part of the product sold e.g. the enterprise sells genetically engineered product. 
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Figure 5: No. of Respondents Using Biotech Processes in R&D, as Part of the 
Production Process and as Part of Product Sold  
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It is useful to distinguish the number of enterprises involved in different biotech areas. 
Around 51 different enterprises were involved in DNA based processes, 81 in 
environmental processes and 132 and 156 in biochemical and bioprocessing based 
processes respectively (see Table 5). 
 
Given the current interest in genetic modification it is relevant to note that 24 
enterprises reported use of genetic engineering (GE) or recombinant DNA- most of 
these being research institutions and universities. 21 used GE for R&D, 6 used it as 
part of the ‘production process’ while 3 used it in ‘production sold’18 (see Table A4). 
Many organisations carry out biotech processes falling under more than one of the 
above categories e.g enterprises using DNA based processes may well also use 
biochemistry and bioprocessing. The converse is less likely to be true; there were a 
number of enterprises that use biochemistry and bioprocessing that were not involved 
in any DNA based processes. 
Enterprises Involved in Different Biotech Areas 
Estimation of the number of processes used per enterprise (Table 6) allows some 
conclusions to be drawn about which types of enterprise were involved in different 
biotech areas: 
 
● The primary products, manufacturing and health services groups were mainly 
involved in biochemistry and bioprocessing based processes.  
● Scientific research and tertiary education enterprises were involved in all areas  
● Local government involvement was mainly confined to environmental and 
bioprocessing based biotech. 
 
Table 6: Number of Processes per Enterprise, by Biotech Area and 
Industrial Grouping 
 
Industrial Group DNA Based Bio-
chemistry 
based 
Environ-
mental 
biotech 
Bio-
processing 
based 
Main Bio-Industry Sector 
Primary Products 1.0 1.5  2.5 Agricultural biotech, Bio-informatics, 
Forest Products, Mining/energy etc 
Food Manufacturing  0.2 2.0 1.0 3.1 Food Processing 
Non-Food 
Manufacturing 
0.3 2.6 0.8 2.8 Agricultural biotech, Food processing, 
environment 
Scientific Research  3.3 5.4 0.9 4.6 All Bio-Industry Sectors 
Local Government 
Administration  
 0.5 2.1 2.0 Environment 
Tertiary Education  7.0 12.0 2.3 11.7 All Bio-Industry Sectors 
Health Services  1.3 6.3 0.1 2.4 Human health biotech 
Other  0.5 1.5 1.0 2.0 Environment, agricultural biotech 
 
                                                 
18 As noted on the title page; all numbers are subject to random rounding to base 3 - so 3 may mean 1, 
2, 3, 4, or 5. 
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2.3 Product and Process Development 
One indication of the rate of innovation by biotech respondents is provided by 
questions such as: “In the last 3 years, has this business implemented a new or 
significantly improved bio-industry sector product/service?”  
Overall, 33% reported implementation of a new product with the innovation rate 
being lowest for local government (9%) and food manufacturers (27%) around 50% 
for four other industrial groups and 33% for tertiary organisations (see Table 7).  
Process innovation rates were fairly similar except for local government and non-food 
manufacturers that implemented significantly more new process (rather than new 
products). 42% of enterprises indicated that they were planning to implement a total 
of 298 new products in the next 3 years, this compares with 180 in the last 3 years. 
Similarly 40% of enterprises reported plans to implement a total of 288 new processes 
(compared to 177 in the last 3 years). This suggests a significant increase in the rate of 
new product and process development.  
Some respondents that were already using biotech processes planned to move into 
new areas or to implement additional processes: 
 
● 9 enterprises that did not use any DNA based process indicated that they 
planned to use at least one of these processes in the future; similarly 
● 9 enterprises that did not use any environmental process indicated that they 
planned to use at least one of these processes in the future (see last column 
Table 5).  
 
The survey included 246 respondents that did not use a biotech process in 1998/99; 
none of these said that they planned to start using specific processes within three 
years, although 3 indicated possible use at some stage. 
 
The frequency distribution for new products and processes is fairly skewed; for 
example 67% had not introduced any new products, 17% had introduced one, 15% 
had introduced two to five new products and 3% had introduced more than five (see 
Table 9. 
Modern Biotechnology Enterprises 
Modern biotechnology enterprises (MBEs) were far more active than other groups in 
new product and process development: 
 
● 57 MBEs introduced a total of 219 new products and processes over the last 3 
years (an average of 3.8 per enterprise); 61% of the total for all groups. 
● 99 Biotech Users (MBU and TBU) introduced a total of 102 new products and 
processes (an average of 1 per enterprise). 
● 68% of MBEs introduced a total of 117 new products and 105 new processes. 
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Table 7: Innovative Output of Biotech Respondents 
 
Industrial Group No. of 
Biotech 
Respondents 
% 
 Reporting 
 Any R&D 
% Implementing 
New Product 
Last 3 Yrs 
% Implementing 
New Process Last 
3 Yrs 
% Planning to 
Implement New 
Product Next 3 
yrs 
Primary Products 6 50% 50% 50% 50% 
Food Manufacturing  33 55% 27% 18% 36% 
Non-Food 
Manufacturing 
24 75% 50% 63% 63% 
Scientific Research  36 92% 42% 50% 58% 
Local Government 
Administration  
33 18% 9% 18% 18% 
Tertiary Education  9 100% 33% 33% 33% 
Health Services  24 13% 50% 38% 50% 
Other  12 50% 50% 25% 25% 
Total  180 55% 33% 33% 42% 
Note: these percentages should be interpreted with caution because of small cell numbers and random 
rounding. 
 
 
Table 8: Number of New Products and Processes 
 
No. of  New Processes Last 3 Yrs Industrial Group No. of  
New 
Products 
Last 3 Yrs 
No. of New 
Products 
Planned in 
Next 3 Yrs
New to 
the 
Business
New to New 
Zealand 
New to the 
World 
Total 
Primary Products 4 6 6 6 2 11 
Food Manufacturing  12 26 6 4 0 6 
Non-Food 
Manufacturing 33 48 36 19 9 42 
Scientific Research  44 84 30 17 15 36 
Local Government 
Administration  4 9 6 1 0 6 
Tertiary Education  24 66 21 14 13 27 
Health Services  44 50 33 1 0 38 
Other  15 9 12 2 0 11 
Total  180 298 144 64 39 177 
Source: (Statistics New Zealand, 2001) 
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Table 9: Frequency Distribution for Number of New Products and Processes 
 
Number of 
Products/ 
Processes 
Planned 
New Product 
Last 3 Yrs 
Planning 
New Product 
Next 3 yrs  
New Process 
Last 3 Yrs 
New to 
Business
New to 
New 
Zealand 
New to 
World 
0 120 67% 105 58% 120 67% 129 147 156 
1 30 17% 18 10% 30 17% 24 18 15 
2-5 27 15% 48 27% 24 13% 18 12 9 
More than 5 6 3% 9 5% 6 3% 9 0 0 
 
 
Innovation rate data is included in OECD and EU innovation surveys but has not been 
systematically collected in New Zealand. An innovation survey commissioned by 
MORST in 1994 asked,  “how many completely new product lines have you 
introduced in the last 5 years?” It was found that the average company had introduced 
16 completely new products over that period (Frater, Stuart, Rose, & Andrews, 1995, 
p. 74). This is a significantly higher level than reported by biotech respondents, 
(averaging one new product per enterprise over the last three years) although this may 
be partly attributable to differences in the survey populations, question formats and 
timeframe. 
 
The OECD has used ‘the share of firms introducing at least one new or improved 
product or process onto the market over a given period’ to compare the innovative 
output of firms in different member countries. The OECD average proportion of  
manufacturing firms that introduced a new product or process in 1994-96  was 56% 
(data from 21 OECD members). For firms with 20-49 employees the share was 
significantly lower – averaging 41% of firms (OECD, 2001, p. 174)– similar to the 
rate of 45% reported by biotech respondents in New Zealand19. 
 
It should be possible to draw further comparisons with other New Zealand industry 
groups once the results of the Business Practices Survey 200020 become available. 
Further work is required before definite conclusions can be reached on the relative 
innovative output of New Zealand biotech firms – although the evidence reviewed 
above does not support the idea that New Zealand biotech firms have a particularly 
high rate of new product or process development.  
 
 
 
 
                                                 
19 The mean for a group of small OECD countries that New Zealand might wish to emulate (Austria, 
Belgium, Denmark, Finland, Ireland, Netherlands, Portugal, Sweden, Switzerland) was 62% for all 
firms and 50% for small firms. 
20 a Statistics New Zealand survey commissioned by the Ministry of Economic Development that 
includes questions on the percentage of enterprises introducing new products/processes over the last 3 
years. 
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3. Characteristics of the Biotechnology ‘Industry’ 
3.1 Industry Sectors 
Modern biotechnology is used in a number of different economic sectors ranging from 
food and non-food manufacturing through various primary industries to health, 
diagnostic and environmental applications.  
 
Table 10: Percentage of Respondents Involved in Different Industry Sectors by 
Biotech Category 
 
 
Modern Biotech Enterprises reported that they were researching and developing 
products, processes and services for use in the ag-bio and human health sectors, 
followed by food processing, genomics/molecular modelling, aquaculture and the 
environment. Food manufacturers were generally classified as MBEs because of their 
use of non-DNA based processes e.g. peptide sequencing, immune stimulants, 
antigens and antibodies etc.  
 
Other biotech categories exhibit a similar pattern while being influenced by the 
industry group of some respondents; so for example: 
 
● the environment industry sector was reported most frequently by Traditional 
Biotech Users –  reflecting  the waste treatment activities of  local authorities; 
● Modern Biotech Users most reported sector was human health – reflecting the 
activities of health services respondents. 
 
A similar pattern emerges when ‘end use sector’ is tabulated against industry group 
(Table A7). The main end use sector is in many cases ‘self defined’: 
 
● Food manufacturers reported food processing as the main end use sector; 
● Non-food manufacturers were mainly involved in ag-bio, human health and 
food processing21; 
● Scientific research organisations were involved in most sectors, ag-bio being the 
most common; 
                                                 
21 Presumably this is because enterprises were assigned to industry groups based on their primary 
activity so ‘non-food manufacturers’ may also be engaged in food processing. 
Industry Sector Modern 
Biotech 
Enterprises
Traditional 
Biotech 
Enterprises
Modern 
Biotech 
Users
Traditional 
Biotech 
Users
All Groups
 Human Health 53% 13% 49% 5% 30%
 Food Processing 42% 38% 8% 29% 33%
 Aquaculture 37% 13% 0% 5% 13%
 Mining/Energy/Petroleum etc 5% 13% 0% 0% 4%
 Forest Products 21% 0% 8% 5% 8%
 Environment 37% 25% 8% 48% 35%
 Ag-Bio 63% 25% 24% 10% 32%
Genomics & Molec' Modelling 42% 0% 0% 0% 12%
Custom Synthesis 21% 0% 0% 5% 8%
Other 21% 0% 16% 10% 13%
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● Local government was mainly involved in environmental processes (water and 
waste treatment) 
● The university and polytechnic group were involved in all areas; human health 
being the most common; 
● Health services organisations were all involved in human health and have some 
involvement in ag-bio and the environment. 
3.2 Strategic Alliances 
Respondents were asked22 about partnerships and alliances for biotechnology activity 
over the last 3 years. Further questions focussed on the purpose of any alliances and 
the types of New Zealand and overseas organisations involved.  
52% of biotech respondents reported a partnership/alliance with a total of 30323 
different organisation types; this suggests that the 93 respondents that had alliances 
had an average of at least three partners each.  
 
Figure 6: Percentage of Respondents Reporting Biotech Alliances 
 
The proportion of respondents reporting a biotech alliance varied markedly between 
industry groups from 100% in tertiary education to a low of 18% for local government 
(Figure 6). Overall 48% reported at least one New Zealand alliance while 30% 
reported an overseas alliance. Overseas alliances were most common in the tertiary 
education, non-food manufacturing and scientific research groups. 
A breakdown of alliance frequency by biotech category reveals that 90% of MBEs 
reported alliances falling to 42% for MBUs and 24% for TBUs. 
The most commonly reported alliance purposes were product/process development – 
reported by 81% of respondents who had an alliance and clinical/field trials (48%). 
13% reported alliances for the purpose of undertaking basic research24. 
                                                 
22 “In the last 3 years did this business have any partnership/alliance for undertaking biotechnology 
activity (research or production)?” 
23 Respondents were not asked how many different organisations they had partnerships with. Data was 
collected on the different types of organisations with which they formed alliances e.g. CRI’s 
businesses, universities etc both in NZ and overseas.  
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Figure 7: Purpose of Biotech Alliances 
Note: this Figure differs from SNZ (2001, p. 19) because from Table 2.06 includes multi unit responses 
– for example the number of (whole) enterprises reporting an alliance for the purpose of 
‘product/processs development’ is 75 (not 96) 
 
 
Overall 33% of respondents reported alliances with CRIs, followed by universities 
(28%) and other businesses (23%). Alliances with CRIs were most common in the 
tertiary education, non-food manufacturing and scientific research groups (Figure 8). 
The relative frequency of the different alliance types seems to be fairly similar across 
the main industry groups. However, further data would be required before any 
conclusion could be drawn as to the relative importance of the different alliance types. 
 
There was a marked difference in the frequency of biotech alliances with other 
businesses and with CRI’s between the different biotech categories: 
 
● 68% of MBEs reported alliances with CRI’s and 47% reported biotech alliances 
with other businesses. 
● For the TBE, MBU and TBU groups; the percentage reporting alliances with 
other businesses was 10% to 17%, while the percentage reporting alliances with 
CRI’s was 14% to 25%. 
 
                                                                                                                                            
24 Based on answers in the ‘other’ category - this may be an underestimate since the questionnaire did 
not include a basic research option. 
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Figure 8: Percentage of Respondents with Different Types of NZ Alliance 
Partners 
 
Note: Base data for Figure 8 is included in Table A8 
 
Respondents were asked whether they had entered into any informal information 
sharing arrangements in the previous three years. 
 
● 58% of respondents had informal agreements (89% of MBEs) 
● 68% of respondents reported either a strategic alliance or an informal agreement 
or both.  
● Most respondents reporting strategic alliances also entered informal agreements, 
however10% reported strategic alliances but not informal agreements and 15% 
reported informal agreements but not strategic alliances. 
● The pattern of informal agreement partner types is very similar to that for 
strategic alliances (see Figure 9) 
 
 
Figure 9: Percentage of Respondents with NZ/Overseas Informal 
Agreements to Share Information 
 
 
 
 
 
 
 
 
 
 
 
This Figure is based on Table 2.072 in SNZ (2001) adjusted for multi unit responses 
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3.3 Intellectual Property Rights25 
 
The Biotechnology Survey included eight questions relating to intellectual property 
(IP) rights and patents covering the following topics: 
 
● Lack of access to IP as a constraint on biotech activities. 
● IP disputes and litigation in the previous three years. 
● Information sharing arrangements. 
● IP acquisition. 
● Patent applications. 
 
15 respondents reported that IP rights issues had hindered development activities26. 
This problems was largely confined to MBEs within the scientific research and 
tertiary education industry groups where 26% -11 out of 43 respondents reported 
problems27.  
 
Projects were abandoned because the enterprise was unable to purchase the IP (9), the 
enterprise was unable to licence the IP (6) or ‘other reasons’ (9).  
 
The survey also collected data on IP related disputes and litigation: 
 
● 12 respondents had been involved in 16 cases of ‘litigation relating to patent 
infringements’; and 
● 15 respondents had been involved in 41 disputes ‘relating to access to research 
information’. 
 
Overall 45 respondents reported at least one IP related problem28. Positive responses 
were concentrated in the MBE category where 47% reported at least one problem. 
While not a major issue for the overall respondent population, IP rights are clearly a 
significant problem for organisations involved in R&D using modern biotech 
processes (MBEs). 
 
Figure 10: Percentage of Respondents Acquiring Intellectual Property 
 Rights from NZ/Overseas by Source 
 
 
 
 
 
 
 
 
 
 
 
This Figure is based on Table 2.073 in SNZ (2001) adjusted for multi unit responses 
                                                 
25 This report section covers material similar to Section 2.07 in Statistics New Zealand (2001) adjusted 
for multi-unit responses. 
26 “Has this business ever had to abandon or not start a biotechnology development activity because 
further work was blocked by IP rights or some knowledge protected by another organisation?” 
27 Problems were reported by 21% (12 out of 57) of Modern Biotech Enterprises  
28 Blocked by IP rights, lack of access to research data, patent litigation, access to research data (Q. 23, 
25, 26, 27) or access to biotech research data reported as a problem (Q. 34). 
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Overall, 25% of respondents acquired the right to use IP in the last accounting year 
(47% of MBEs). The main sources were other businesses (NZ and overseas), 
universities and CRI’s (see Figure 9). 
Patents 
Only a small proportion of biotech respondents had made any patent applications  
 
● In the year to June 1999, 21 enterprises (12% of biotech respondents) made a 
total of 56 successful patent applications.  
● Nine respondents made 80% of all biotech patent applications in the year to 
June 1999. 
● In the previous five years, 33 enterprises (18% of respondents) had made a total 
of  156 successful patent applications (147 by MBEs). 
● Nine respondents made 70% of all biotech patent applications in the previous 
five years. 
 
See Marsh (2001a) and van Beuzekom (2001) for a comparison of New Zealand’s 
biotech patenting rate with that of other OECD countries. 
Biotech Related Conference and Publishing Activity 
Survey respondents were asked whether any staff member had been involved in 
biotech related conference and publishing activity in the 12 months to June 1999. 
 
● At least one member of staff from 70% of respondents had attended a national 
or international conference ‘on a biotechnology subject’; 
● Staff from 32% of respondents had presented a research paper at a biotech 
conference; 
● Staff from 22% of respondents had published an article on biotechnology in a 
refereed journal. 
 
A breakdown of respondents by biotech category (Table 11) shows that there are 
marked differences between the different groups: 
 
● MBEs have a markedly higher rate of conference and publishing activity: 95% 
of respondents had been involved in a biotech conference and staff from 58% 
had published a refereed journal article; 
● Only 43% of TBUs had staff attending a biotech conference and there were no 
refereed journal articles. 
 
Table 11: Percentage of Respondents with Staff Attending Biotech Related 
Conferences and Publishing Refereed Journal Articles 
  
Activity Modern 
Biotech 
Enterprises 
Traditional 
Biotech 
Enterprises 
Modern 
Biotech 
Users 
Traditional 
Biotech 
Users 
All Groups 
Attend Conference 95% 63% 92% 43% 70% 
Present Conference Paper 68% 13% 25% 10% 32% 
Publish Ref'd Journal Article 58% 13% 8% 0% 22% 
This Table differs from Table 2.075 in SNZ (2001) because of adjustment for multi-unit responses 
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3.4 Income, Expenditure and Exports 
Survey respondents estimated that income of $475 million was attributable to modern 
biotechnology, in the year ended June 1999 - $326 million from private sector 
respondents, $149 million from the public sector. This compares to respondents 
income from all sources of $7.25 billion i.e overall biotech provided around 7% of 
income for the 180 biotech using enterprises.  
 
Various difficulties associated with the data on income and expenditure mean that 
these estimates should be treated with caution. Enterprises were asked to estimate the 
proportion of their total income and expenditure that could be attributed to 
biotechnology. Such an instruction is open to widely varying interpretations29, so for 
example dairy product manufacturers estimates varied between zero and 100% of 
their income.  
 
15% of enterprises which use biotech processes reported that they received no income 
attributable to biotechnology. 73% received less than 50% of their income from 
biotech, while 15% attributed all of their income to biotech (see Table 12 below). 
 
Within the MBE group 53% received 0 > 25% of their income from biotech, while 
15% (around 9 enterprises) received all of their income from biotech – such firms are 
commonly termed Dedicated Biotechnology Firms (DBF) in the international 
literature (see Table 12 below). 
Table 12: Biotech Income as a % of Total Income 
 
Industrial Group 
  
0 0 > 25% 25 > 75% 75 > 100% 100% 
Food Manufacturing & Primary Products 29% 50% 7% 0% 7% 
Non-Food Manufacturing 13% 13% 25% 13% 38% 
Scientific Research  8% 54% 15% 8% 15% 
Local Government Administration  36% 45% 18% 0% 0% 
Health Services  0% 38% 38% 13% 25% 
Other  25% 25% 25% 0% 0% 
Modern Biotech Enterprises 5% 53% 16% 11% 16% 
All Groups 15% 47% 17% 5% 15% 
Number of Respondents 27 84 30 9 27 
 
 
Biotech respondents reported total exports of $1.75 billion and biotech exports of the 
order of $170 million. 42% (75) of biotech respondents reported exports, while 
biotech exports were reported by 23% (42). 
The value of biotech exports was generally less than $1 million (57% of those 
reporting exports). 29% reported biotech exports of $1 to $10 million while 14% 
(around 6 enterprises) reported biotech exports of $10 to $100 million. 
 
                                                 
29 depending on interpretation of ‘attributable’ and whether the respondent concentrated only on 
modern biotech. Based on a broad interpretation it could be said that all dairy manufacturing income is 
attributable to biotech. Separation of the proportion of this attributable to modern biotech would be 
very difficult. These issues are also discussed in Statistics New Zealand (2001). 
Modern Biotechnology In New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99 
 
Department of Economics, University of Waikato  
 
24
Table 13: Biotech Respondents Income, Expenditure and Exports  
by Industrial Group 
 
Industrial Group Total Income Biotech 
Income 
Total Exports Biotech 
Exports 
Primary Products c c c c 
Food Manufacturing  3,954 109 1,691 c 
Non-Food 
Manufacturing 685 110 0 c 
Scientific Research  669 88 31 c 
Local Government 
Administration  556 11 c c 
Tertiary Education 33030 29 c c 
Health Services  188 74 c c 
Other  c c c c 
Sum of Confidential 
Cells ( c) 873 55 33 168 
Total  7,254 475 1,755 168 
Note: c indicates cell ‘confidentialised’ to give effect to the confidentiality provisions of 
the Statistics Act 1975 
 
Some key points derived from Table 13 include: 
 
● 80% of biotech income was attributable to four industrial groups (food and non-
food manufacturers, research and health services); 
● The relative importance of biotech to respondents varies from 40% in the health 
services group (mainly laboratories which use biotech processes) to less than 
3% for food manufacturers (e.g. dairy product manufacturers). 
● The food manufacturing group contains a number of very large enterprises that 
account for over 96% of respondents total exports. 
 
The estimated value of biotech exports should be viewed with considerable caution 
(see Footnote31 below). Confidentiality requirements mean that a breakdown of 
biotech exports by industrial group cannot be published. 
 
 
                                                 
30 This is an underestimate since it is partly based on aggregation of multi-unit responses rather than 
single responses for  ‘whole’ institutions. 
31 This estimate should be viewed with considerable caution – hopefully it is of the right order of 
magnitude. Total and biotech exports have been estimated based on the assumption that ‘total 
production of goods/services’ is approximately equal to total income – thus Q.21 (exports as a % of 
total production) * total income = total exports and Q. 22 (biotech exports as a % of total production) * 
total income = biotech exports. In certain cases the resultant value of biotech exports exceeds reported 
biotech income. In these cases biotech exports were taken to be the same as biotech income. This had 
the effect of reducing the estimated level of biotech exports from $325 million to $168 million.  
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3.5 Human Resources 
 
Survey respondents were asked to provide data on their employees ‘supporting 
biotech activity’ including: 
 
● a headcount as at 30 June 1999, broken down by staff qualification; and 
● Full time equivalents in the year to 30 June. 
● they were specifically asked not to include staff performing indirect support to 
biotech activities e.g. central finance or personnel or other similar centralised 
support services. 
 
Figure 11: Number of Biotech Employees by Qualification and Industrial Group 
Survey respondents reported that a total of 3057 (or 2984 full time equivalent) staff 
supported biotech activity. Around 67% were graduates and 26% had PhD’s. 
 
● The largest employee group came from the health services industrial group, 
followed by the tertiary education and research groups (see Figure 10). 
● Most graduates were employed by the tertiary education and research groups 
(most health services biotech employees are not graduates). The concentration 
of qualified staff is most marked for staff with PhDs – 88% of these were 
employed within these two groups. 
● MBEs employed 1667 biotech staff (FTE) – 56% of the total for all 
respondents.  
● Employment of qualified staff was heavily concentrated in MBEs; they 
employed 83% of biotech graduates and 95% of PhDs 
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3.6 Problems Affecting Biotech R&D 
The survey questionnaire included a question on “constraints to biotechnology 
research and development activities faced by this business over the accounting 
period”. ‘Catch-all’ question of this type do not attempt to measure the seriousness of 
each issue and so may overstate problems. Nonetheless they can provide a valuable 
snapshot on the relative importance of various problems facing the industry. 
 
● Around 59% of respondents reported at least one problem affecting biotech 
R&D (most of the remainder did not report any R&D activity); 
● Around 79% of respondents involved in R&D reported at least one problem; 
● 89% of MBEs reported at least one problem. 
● Enterprises engaged in R&D tended to report a wider range of problems (3.5 per 
enterprise for MBEs, 2.4 for TBEs, 1.2 for MBUs and 0.5 for TBUs). 
 
The problems reported most frequently by all respondents were access to capital and 
regulations. Problems were reported most widely in the tertiary education and 
research industrial groups, where again access to capital and regulations were cited 
most frequently. 
 
Table 14:  Problems Affecting Biotech R&D, by Industrial Group 
 
Table 15:  Problems Affecting Biotechnology, by Category 
 
 
 
Primary 
Products
Food 
Manuf'
Non 
Food
Scientific 
Research
Local 
Gov't
Tertiary 
Education
Health 
Services
All 
Groups
Access to Capital 0% 18% 38% 58% 0% 67% 63% 35%
Access to Management Experts 0% 0% 25% 25% 9% 0% 13% 13%
Access to Trained Biotech Experts 100% 18% 25% 33% 0% 67% 25% 23%
Experienced Biotech Experts 50% 18% 38% 25% 9% 67% 25% 22%
Access to Biotech Research Data 0% 9% 25% 17% 9% 33% 13% 10%
Acess to Technology 0% 18% 25% 25% 0% 33% 25% 20%
Lack of Market Information 0% 9% 25% 25% 0% 67% 13% 17%
Regulations 50% 9% 50% 58% 0% 67% 13% 28%
Implications of Treaty of Waitangi 0% 0% 13% 8% 0% 67% 0% 8%
Other Problems 0% 9% 0% 8% 9% 67% 13% 10%
Modern 
Biotech 
Enterprises
Traditional 
Biotech 
Enterprises
Modern 
Biotech 
Users
Traditional 
Biotech 
Users
All Groups
Access to Capital 63% 38% 42% 10% 35%
Access to Management Experts 26% 25% 0% 5% 13%
Access to Trained Biotech Experts 42% 25% 17% 5% 23%
Experienced Biotech Experts 42% 38% 17% 5% 22%
Access to Biotech Research Data 16% 13% 8% 5% 10%
Acess to Technology 37% 38% 8% 5% 20%
Lack of Market Information 32% 13% 8% 5% 17%
Regulations 63% 25% 17% 10% 28%
Implications of Treaty of Waitangi 21% 0% 8% 0% 8%
Other Problems 16% 0% 17% 5% 10%
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4. International Comparisons 
National statistics on biotechnology use are available from some governments and  
various private sector reports32. Five OECD members collect data on biotech 
expenditure and human resources as part of their national R&D surveys. Only three 
countries have undertaken specific biotech surveys – Canada, France and New 
Zealand. International comparisons are difficult because of wide variation in data 
collection methods and definitions. The Statistics New Zealand biotech survey was 
closely modelled on work carried out by Statistics Canada thus enabling some 
comparisons to be made. However there are some important differences; the New 
Zealand definition of biotech included several additional processes and so was 
somewhat wider than that used in Canada; the number of biotech firms is also not 
directly comparable since the Canadian survey excluded firms that had less than 5 
employees and less than C$100,000 R&D expenditures33.  
 
An approximate comparison between the two data sets is included as Table 16. It is 
based on application of the Statistics Canada definition of a biotech enterprise to the 
New Zealand data set – namely enterprises which conduct R&D, have a minimum of 
five biotech employees and biotech expenditure of at least NZ$150,000. Data for 
Australia is also included although based on a narrower definition (see footnote 34). 
 
Table 16: Biotechnology in New Zealand, Canada and Australia 
 
 Canada 
1999 
Australia 
1998/99 
NZ 
1998/99 
Population (1997)  30.3 18.5 3.8 
No. of biotech enterprises  358 12034 39 
Total Biotech revenue35 (NZ$ m)  2850 1077 205 
Biotech revenue per million population (NZ$ m)  94 58 54 
Revenue per firm (NZ$ m)  8.0 9.0 5.3 
Biotech related employees (Headcount)  7695 3801 1708 
Biotech related employees per million population  254 205 449 
% of products and processes in R&D stage  49% 47%36 72% 
Data for Canada is extracted from McNiven (2001) and Ernst & Young (1999) 
 
New Zealand’s biotech revenue per million population (NZ$54 million) is rather 
lower than Canada's (NZ$94 million), but the difference is fairly small considering 
Canada’s higher per capita income and proximity to the United States. New Zealand 
has a rather lower mean revenue per biotech firm ($5.3m vs $8.0m); consistent with 
                                                 
32 Pattinson, Van Beuzekom, & Wyckoff (2001) provide a useful summary of existing sources of 
national statistics on biotechnogy. 
33 These firms were responsible for less than 1% of biotech R&D expenditure. 
34 No. of ‘core’ biotech firms whose business is entirely or substantially biotechnology related and that 
have a significant commitment to technological innovation, excludes traditional biotech operations and 
not for profit enterprises. See Ernst & Young (1999) and van Beuzekom (2001). 
35 Based on an exchange rate of NZ$1.5= C$1 
36 Includes ‘under development’ (33%) and ‘clinical/field trial stage’ (14%), see Ernst & Young (1999, 
p. 17) 
37 Based on an exchange rate of NZ$1.5= C$1 
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the predominance of SMEs in the New Zealand economy. New Zealand appears to 
have a significantly higher rate of biotech employment; further investigations will be 
undertaken to try and confirm this. There is some evidence that use of biotech 
processes in New Zealand is at an earlier stage with 72% being at the R&D stage 
against 49% in Canada38. 
 
 
 
                                                 
38 Some of this difference may result from differences in variable definition 
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5. Modern Biotech Enterprises in New Zealand 
 
5.1 Introduction 
Policy makers and academics have a particular interest in modern biotech enterprises 
since their performance will be crucial in determining New Zealand’s overall 
performance in the biotech area. Much of the international biotech literature focuses 
on this group so a separate description should be useful, both for international 
comparison and for domestic policy makers. 
 
This section describes the characteristics of Modern Biotech Enterprises (MBEs) that 
use at least one modern biotech process (see Table 1); conduct R&D involving at least 
one modern biotech process; and employ at least one (FTE) graduate that ‘supports 
biotechnology activity’. Such a definition is broadly consistent with the Statistics 
Canada definition of a biotechnology firm (see chapter 4 above). 
 
5.2 Enterprises Involved 
New Zealand had 57 MBEs in 1998/99, spread across various industrial groups 
particularly scientific research organisations (24) primary product and manufacturing 
enterprises (15) and Universities (6). They included 42 enterprises which developed 
and used DNA based processes and 24 which developed and used genetic engineering 
or recombinant DNA.  
 
45 of the 57 MBEs fall under 6 ANZSIC categories (at the 5 digit level): Scientific 
Research, Higher Education, Medicinal and Pharmaceutical Product Manufacturing, 
Dairy Product Manufacturing, Technical Services nec and Hospitals (except 
psychiatric). Modern biotech enterprises were split fairly evenly between the private 
sector (30) and the public sector (27). 
 
5.3 Biotech Processes 
57 Modern Biotech Enterprises reported use of 1060 processes – an average of 19 
processes per enterprise – compared to 5 per enterprise for biotech users (see Table 4). 
 
69% of MBEs use DNA based processes, almost all used bioprocessing and 
biochemistry based processes, around half used environmental biotech (Table A6). 
 
5.4  Product and Process Development 
Over the previous three years: 
 
● 68% of MBEs had introduced a new product or process. 
● MBEs had introduced 114 new products and 105 new processes. 
● 26% of MBEs introduced a total of 30 ‘New to the World’ processes. 
 
In the next three years: 
 
● 67% plan to introduce a new product and 74% plan to introduce a new process. 
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● MBEs plan to introduce 207 new products and 219 new processes. 
 
5.5  Industry Sectors 
Modern Biotech Enterprises were most involved in the ag-bio (63% of MBEs) and 
human health sectors (53%), followed by food processing (42%), genomics/molecular 
modelling (42%), aquaculture and the environment (Table 10). 
 
5.6  Strategic Alliances 
90% of MBEs reported alliances with a total of 227 different organisation types; this 
suggests that the 51 MBEs that had alliances had an average of at least 4 partners 
each.  
 
89% of MBEs reported informal information sharing agreements. 
 
5.7 Intellectual Property Rights 
47% of MBEs reported at least one IP related problem39. While not a major issue for 
the overall respondent population, IP rights are clearly a significant problem for 
organisations involved in R&D using modern biotech processes (MBEs). 
 
Patents 
● In the year to June 1999, 21 enterprises (37% of MBEs) made a total of 54 
successful patent applications (no patent applications were made by other 
respondent groups) 
● In the previous five years, 27 enterprises (47% of MBEs) had made a total of  
147 successful patent applications (94% of  patent applications by all 
respondent groups). 
 
Biotech Related Conference and Publishing Activity 
● 95% of MBEs had been involved in a biotech conference. 
● Staff from 58% of MBEs had published a refereed journal article. 
 
5.8 Income, Expenditure and Exports  
MBEs estimated that income of $236 million was attributable to modern 
biotechnology, in the year ended June 1999 - $122 million from private sector 
respondents, $115 million from the public sector.  
 
This compares to MBE income from all sources of $2.1 billion i.e overall biotech 
provided around 11% of income for the 57 MBEs.  
 
                                                 
39 Blocked by IP rights, lack of access to research data, patent litigation, access to research data (Q. 23, 
25, 26, 27) or access to biotech research data reported as a problem (Q. 34). 
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Within the MBE group 53% received 0 > 25% of their income from biotech, while 
15% (around 9 enterprises) received all of their income from biotech – such firms are 
commonly termed Dedicated Biotechnology Firms (DBF) in the international 
literature. 
 
MBEs reported total exports of $300 million and biotech exports of the order of $60 
million. 47% of MBEs reported exports, while biotech exports40 were reported by 
26% (around 9 had exports up to $1million, while 6 had exports in the range $1-$10 
million). 
 
5.9 Human Resources 
MBEs employed 1667 biotech staff (FTE) – 56% of the total for all respondents.  
 
Employment of qualified staff is heavily concentrated in MBEs; they employed 83% 
of biotech graduates and 95% of PhDs. 
 
5.10 Problems Affecting Biotech R&D 
The problems most frequently reported by MBEs were access to capital, regulations, 
and access to trained/experienced biotech experts. 
 
● 89% of MBEs reported at least one problem affecting biotech R&D. 
● MBEs tended to report a wider range of problems (3.5 per enterprise for MBEs 
compared to 2.4 for TBEs, 1.2 for MBUs and 0.5 for TBUs). 
                                                 
40 The estimated value of biotech exports should be viewed with considerable caution (see Footnote on 
page 23). 
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Appendix Tables 
 
Table A1: Breakdown of Biotech Respondents by ANZSIC Classification 
 
A021900 Services to Agriculture  
A030100 Forestry 6 
B120000 Oil and Gas Extraction  
C212900 Dairy Product Manufacturing 6 
C211200 Poultry Processing  
C212100 Milk and Cream Processing  
C212200 Ice Cream Manufacturing  
C213000 Fruit and Vegetable Processing 12 
C215200 Cereal Food and Baking Mix Manufacturing  
C216100 Bread Manufacturing  
C217300 Seafood Processing  
C217900 Food Manufacturing nec  
C218200 Beer and Malt Manufacturing  
C218400 Spirit Manufacturing 6 
C218300 Wine Manufacturing 9 
C233100 Pulp, Paper and Paperboard Manufacturing  
C253400 Organic Industrial Chemical Manufacturing  
C253500 Inorganic Industrial Chemical 9 
C254400 Pesticide Manufacturing  
C254600 Cosmetic and Toiletry Preparation Manufacturing  
C254900 Chemical Product Manufacturing  
C272200 Aluminium Smelting  
C254300 Medicinal and Pharmaceutical Product Manufacturing 15 
F451200 Cereal Grain Wholesaling  
F452300 Chemical Wholesaling 3 
F471700 Liquor Wholesaling  
F479600 Pharmaceutical and Toiletry Wholesaling  
L781000 Scientific Research 24 
L782900 Technical Services nec 6 
M811300 Local Government Administration 33 
N843100 Higher Education 12 
O861100 Hospitals (except Psychiatric hospitals) 15 
O863100 Pathology Services  
O863900 Health Services nec 9 
O864000 Veterinary Services  
P923900 Recreational Parks and Gardens  
Q952500 Gardening Services  
Q963400 Waste Disposal Services  
D370100 Water Supply 9 
D370200 Sewerage and Drainage Services  
M811100 Central Government Administration  
L785500 Business Management Services  
L782300 Consultant Engineering Service  
  Total 180 
 
Modern Biotechnology In New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99 
 
Department of Economics, University of Waikato  
 
33
Table A2: Industrial Grouping vs Institutional Type 
 
Industrial Group Private Private  
Non-
Profit 
Central 
Govern-
ment  
Local and 
Regional 
Govern-
ment 
Total 
Primary Products 6 0 0 0 6 
Food Manufacturing  36 0 0 0 36 
Non-Food 
Manufacturing 24 0 3 0 27 
Scientific Research  24 6 9 0 36 
Local Government 
Administration  0 0 0 33 33 
Tertiary Education 0 0 9 0 9 
Health Services  6 0 18 0 24 
Other  6 0 3 3 9 
Total  99 6 45 36 180 
Note Private includes ‘Corporate and Non-Corporate Enterprises’. Central 
Government includes ‘Producer Enterprises’ and ‘Non-market Organisations’ 
 
 
 
Table A3:  Biotech Category vs Industrial Group 
 
Industrial Group Modern 
Biotech 
Enterprises 
Traditional 
Biotech 
Enterprises 
Modern 
Biotech 
Users 
Traditional 
Biotech 
Users 
All Biotech 
Respondents 
Primary Products  3 0 0 3 6 
Food Manufacturing 3 9 6 18 36 
Non-food 
Manufacturing 9 6 3 3 24 
Scientific Research  24 6 3 3 36 
Local Government 
Administration  0 0 3 30 30 
Tertiary Education 6 0 3 3 9 
Health Services  6 0 18 0 27 
Other 3 0 3 6 12 
Total 57 24 36 63 180 
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Table A4: Details of Respondents Using Biotech Processes and Stage of Use 
Process If no plan .. because
R&D/ 
Process 
Develop-
ment
Part of 
Production 
Process
Part of 
Product 
Sold
No 
application 
to this 
business
Not cost 
effective
DNA Based
GE 24 21 6 3 9 144 6
Gene Probes 42 30 12 6 12 126 9
Bio Informatics 30 30 6 3 9 141 6
Genomics 24 21 6 3 9 147 3
Pharmacogenetics 6 6 3 3 9 162 3
DNA Sequencing 27 24 6 3 9 141 6
DNA Synthesis 18 15 3 3 3 150 9
DNA Amplification 45 33 18 9 3 132 3
Gene Therapy 3 6 0 0 3 168 6
Rational Drug Design 9 9 0 0 6 165 3
Other DNA Based 3 3 3 0 0 36 0
Biochemistry Based
Vaccines 24 12 15 6 6 147 3
Immune Stimulants 33 24 15 12 3 144 3
Drug Design 18 15 6 3 9 159 3
Combinatorial Chem 9 9 0 3 9 165 3
Diagnostic Tests 66 39 39 21 3 111 6
Peptide Synthesis 9 12 3 0 6 162 9
Peptide Sequencing 24 24 3 0 3 150 6
Cell Receptors 27 21 6 6 6 150 3
Cell Signalling 21 18 3 3 9 156 3
Bio-sensing 30 18 15 6 15 132 9
Pheromones 12 9 6 0 6 165 3
Molecular Modelling 18 18 0 0 6 156 3
Structural Biology 21 21 0 0 6 156 6
Antigens 51 30 27 15 6 126 0
Monoclonal Antibodies 48 27 27 12 6 126 6
Antibodies 54 33 33 18 3 123 6
Microbiology 105 54 72 33 3 75 3
Biomaterials 57 36 30 27 3 120 3
Other Biochemistry 0 3 0 0 0 39 0
Environmental Biotechnologies
Bioaugmentation 48 21 33 9 3 126 6
Bio-reactors 51 24 39 9 6 120 9
Biological Gas Cleaning 9 3 6 3 3 165 6
Bio-remediation 39 18 27 3 6 132 9
Phytoremediation 36 12 27 6 6 138 6
Other Environmental 3 0 0 0 0 30 0
Bioprocessing Based
Cell Culture 69 42 48 15 3 99 9
Tissue Culture 51 36 27 12 3 126 9
Embryo Culture 15 12 9 3 0 156 6
Cell Manipulation 30 21 12 3 3 147 6
Tissue Manipulation 18 18 6 3 0 159 3
Embryo Manipulation 9 9 3 0 3 165 6
Fermentation 54 24 39 12 3 123 6
Bioprocessing 36 18 27 9 3 141 3
Biotransformation 42 21 21 15 0 138 3
Bio-leaching 0 0 0 0 3 174 3
Bio-pulping 3 3 3 0 6 171 0
Bio-bleaching 3 3 0 0 3 174 0
Bio-desulphurisation 0 0 0 0 0 177 3
Bio-pesticide mfg 18 12 6 6 3 159 3
Extraction 54 39 33 24 3 126 0
Biofiltration 42 12 30 3 9 126 6
Bioindicators 69 27 45 9 3 108 3
Micro-Selected Breeding 15 12 9 9 6 153 6
Natural Products 45 36 21 15 9 126 3
Microbio-inoculants 9 9 3 3 3 168 3
Somatic Embryo-genesis 12 12 6 3 0 162 6
Other Bioprocessing 3 3 0 0 0 36 0
Used Stage of Use Plan to 
Use in 
Next 3 
Years
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Table A5: Number of Enterprises Involved in Different Biotech Areas by 
Industrial Group 
 
Biotech Area Primary, 
Food & 
Non-Food 
Manufact-
urers and 
Other 
Research 
Organ-
isations 
Univers-
ities 
etc 
Health 
Organ-
isations 
Local 
Auth-
orities 
No. of 
Enter-
prises 
Involved 
in each 
stage 
DNA Based 
Processes 
9 24 9 12 0 51 
Biochemistry 
Based 
57 30 12 24 9 132 
Environmental 
Biotech 
33 15 6 3 27 81 
Bioprocessing 
Based 
69 33 6 21 27 156 
Total No of 
Enterprises 
involved at any 
stage 
75 36 9 24 33 180 
 
 
 
Table A6: Number of Enterprises Involved in Different Biotech Areas by Biotech 
Category 
 
 
Biotech Area Modern 
Biotech 
Enterprises 
Traditional 
Biotech 
Enterprises 
Modern 
Biotech Users
Traditional 
Biotech Users 
All Biotech 
Respondents 
DNA Based 
Processes 
42 0 9 0 51 
Biochemistry 
Based 
57 12 33 30 132 
Environmental 
Biotech 
27 9 9 36 81 
Bioprocessing 
Based 
54 18 33 51 156 
Total No of 
Enterprises 
involved at any 
stage 
57 21 36 63 180 
 
 
Modern Biotechnology In New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99 
 
Department of Economics, University of Waikato  
 
36
Table A7: Percentage of Respondents Involved in Different Industry Sectors by 
Industry Group 
 
 
 
 
Table A8: Alliance Frequency by Industry Group 
 
Industrial Group % of respondents with % of respondents reporting 
alliance with 
  
No. in 
Group 
Any 
Strategic 
Alliance
NZ 
Alliance
Overseas 
Alliance
CRI University 
or 
Polytech 
Business
Primary & Food Manufacturing 39 54% 31% 15% 23% 23% 15% 
Non Food Manufacturing 24 88% 75% 50% 50% 50% 38% 
Scientific Research 36 75% 67% 42% 50% 42% 33% 
Local Government Administration 33 27% 18% 9% 9% 0% 9% 
Tertiary Education 9 100% 100% 67% 100% 67% 67% 
Health Services 24 50% 38% 13% 13% 13% 25% 
Other 12 50% 25% 25% 25% 25% 0% 
All Groups 180 52% 48% 30% 33% 28% 23% 
 
 
 
Table A9: Informal Agreements to Share Information 
 
Classification of 
Partner 
Partner in New Zealand Partner Outside New Zealand 
 Number Percentage of 
Respondents 
Number Percentage of 
Respondents 
Another Business 60 33% 45 25% 
University 51 28% 24 13% 
Crown Research 
Institute 
66 37% 0  
Hospital 24 13% 3 2% 
Other 12 7% 3 2% 
This Table is based on Table 2.072 adjusted for multi unit responses 
Food 
Manufact-
uring
Non Food Scientific 
Research
Local 
Govern-
ment
Tertiary 
Educ-
ation
Health 
Services
All 
Groups
 Human Health 0% 38% 33% 0% 100% 100% 28%
 Food Processing 91% 38% 25% 0% 67% 0% 32%
 Aquaculture 9% 13% 25% 0% 67% 0% 13%
 Mining/Energy/Petroleum etc 0% 0% 0% 0% 33% 0% 2%
 Forest Products 0% 13% 8% 0% 33% 0% 8%
 Environment 9% 13% 42% 82% 67% 13% 35%
 Ag-Bio 9% 63% 58% 18% 67% 13% 32%
Genomics & Molec' Modelling 0% 0% 33% 0% 67% 0% 12%
Custom Synthesis 0% 13% 17% 0% 33% 0% 8%
Other 9% 13% 25% 9% 67% 0% 15%
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Table A10: Income, Expenditure and Exports by Biotech Category ($ millions) 
 
Industrial Group Modern 
Biotech 
Enterprises 
Traditional 
Biotech 
Enterprises
Modern 
Biotech 
Users 
Traditional 
Biotech 
Users 
Sum of 
Confidential 
Cells ( c) 
All  
Biotech 
Respondents
Total Income 2,124 1,008 1,647 2,475  0 7,254 
Biotech Income 236 68 112 59  0 475 
Total Exports 301 c c c  1,454 1,755 
Biotech Exports 60 c 40 c 70 170 
 
 
Table A11: Breakdown of Biotech Employees by Qualification and Industrial 
Group 
 
 RD 
Headcount 
RD 
FTE 
PhD MSc BSc Certificate Other 
Qualification
Primary Products 55 50 12 3 12 6 0 
Food Manufacturing  230 190 6 15 80 55 25 
Non-Food manufacturing 370 320 25 30 90 35 100 
Scientific Research  780 610 310 110 210 60 20 
Local Government Administration 95 40 0 3 15 65 6 
Tertiary Education 700 630 310 210 180 45 15 
Health Services  800 1,100 30 18 140 310 150 
Other  45 40 12 9 18 12 3 
Total  3057 2984 703 388 733 588 315 
 
 
Table A12: Breakdown of MBEs by ANZSIC Classification 
 
A021900 Services to Agriculture 3 
A030100 Forestry  
C212900 Dairy Product Manufacturing 6 
C254300 Medicinal and Pharmaceutical Product Manufacturing 9 
L781000 Scientific Research 21 
L782900 Technical Services nec 3 
N843100 Higher Education 6 
O861100 Hospitals (except Psychiatric hospitals) 3 
L785500 Business Management Services 3 
C218200 Beer and Malt Manufacturing  
C254600 Cosmetic and Toiletry Preparation Manufacturing  
D370100 Water Supply  
L782300 Consultant Engineering Service 6 
M811100 Central Government Administration  
O863900 Health Services nec  
P923900 Recreational Parks and Gardens  
  Total 57 
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Table A13: Definition of ‘Modern’ and ‘Traditional’ Processes 
DNA Based 
 
  
Notes:  
i. ‘Modern’ biotech processes (for the purpose of this report) are represented in 
normal font, white background.  
ii. ‘Traditional’ biotech processes in italic, grey background. 
iii. Statistics Canada categories refer to 1999 questionnaire in McNiven (2001). 
iv. * indicates allocation to Statistics Canada category is probably correct but 
needs to be reviewed. 
SNZ Q 
No.
Process Definition in Biotechnology Survey 1998/99 Stat's 
Canada 
Categ'y
5.1 Genetic 
Engineering/Recombinant 
DNA
The manipulation of an organism’s genetic material by introducing or 
eliminating specific genetic changes through modern molecular biology 
techniques.
1140
5.2 Gene Probes A section of DNA or RNA of known structure or function which is marked 
with a radioactive isotope, dye or enzyme that can be used to detect the 
presence of a similar sequence from any biological material
1110
5.3 Bio Informatics Computer-based analysis of biological information (bio-info), especially 
genomics and molecular modelling (eg DNA/RNA/ protein sequencing and 
databases for genes of humans, plants, animals and micro-organisms)
1120
5.4 Genomics The use and organisation of information of biological interest, including 
the construction and analysis of genes that may be used to search for new 
genes of interest, matching existing genes etc.
1140
5.5 Pharmacogenetics The study of the genetics of drug production, action or assimilation 1140
5.6 DNA Sequencing A method to determine the order of nucleotides on a gene or DNA 
fragment
1140
5.7 DNA Synthesis Design and synthesis of a DNA molecule from existing information of its 
constituent bases
1140
5.8 DNA Amplification Process of increasing the number of copies of a particular gene of 
chromosomal sequence
1140
5.9 Gene Therapy Replacement of a defective gene in an organism suffering from a genetic 
defect
1140 *
5.10 Rational Drug Design Analysis of the structures of active sites of enzymes and receptors in order 
to design pharmocologically active synthetic molecules
1160
5.11 Other DNA Based 
DNA Based Processes: Technology using chemistry of DNA as a major component
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Table A13 (cont): Definition of ‘Modern’ and ‘Traditional’ Processes 
Biochemistry/Immunochemistry Based 
 
 Notes:  
‘Modern’ biotech processes (for the purpose of this report) are represented in normal font, white 
background.  
‘Traditional’ biotech processes in italic, grey background. 
* indicates Statistics Canada category is probably correct but needs to be reviewed. 
SNZ Q 
No.
Process Definition in Biotechnology Survey 1998/99 Stat's 
Canada 
Categ'y
6.1 Vaccines The agent containing antigens produced from killed, attenuated or live 
pathogenic micro-organisms or their genetic material used to stimulate the 
immune system to protect the host
1150
6.2 Immune Stimulants Compounds that induce the immune system to produce antibodies or 
antibody containing lymphocytes
1150
6.3 Drug Design and Delivery Development of drugs where the raw materials and/or processes involve 
the use of biotechnology
1160
6.4 Combinatorial Chemistry An approach to chemical synthesis that enables the creation of large 
numbers of organic compounds by putting chemical building blocks 
together in every possible combination. It is used to synthesise novel 
compounds, which are screened, or tested, against biological targets as part 
of the drug discovery process 
1200
6.5 Diagnostic Tests A test used to determine the source of a problem or a method of 
determining the nature of a disease by analysing the symptoms 
1170
6.6 Peptide/Protein Synthesis Procedure to link two or more amino acids joined by a linkage called a 
peptide bond
1180
6.7 Peptide/Protein Sequencing The process of determining the sequence of a polypeptide or cluster of 
polypeptides, or the process of creating a new substance from precursor 
molecules
1180
6.8 Cell Receptors Functional proteinaceous structures found in the membrane (surface) of 
cells that tightly bind specific molecules (organic, protein or viruses).
1190
6.9 Cell Signalling The mechanism used by cells to induce or trigger events at remote sites 
within cells
1190
6.10 Bio-sensing Use of biological molecules (eg enzymes, antibodies) in conjunction with a 
transducer to low level detection of substances such as sugars and proteins 
in body fluids, pollutants in water etc.
none
6.11 Pheromones Compounds emitted by insects and spread through the air for the purpose 
of attracting the opposite sex
1190
6.12 Three Dimensional Molecular 
Modelling 
Description of the characteristics of molecules through a 3D spatial 
representation
1200
6.13 Structural Biology The study of the three dimensional structures of biological molecules(such 
as proteins) and their mutual interactions as a means of understanding the 
functions of these molecules within the cell
1190
6.14 Antigens A substance that stimulates the production of specific neutralizing 
antibodies in an immune response. Any chemical substance, usually protein 
that interacts with an antibody
1170 *
6.15 Monoclonal Antibodies A monoclonal antibody is a highly specific antibody which is derived from 
a line of specialised cells and which recognises only one specific 
complimentary antigen
1170
6.16 Antibodies Proteins that circulate in the blood stream and bind to foreign invading 
substances (antigens eg bacteria, toxins, certain viruses) with a great deal 
of specificity
1170
6.17 Microbiology/Microbial 
Ecology
Study of organisms that are too small to be seen with the naked eye 1220
6.18 Biomaterials Any biologically derived material which is used for its material properties 
rather than its biological properties
none
6.19 Other Biochemistry 
Biochemistry/Immunochemistry Based: Technology which utilises immunochemistry/antibodies or 
enzymes as a major compnent
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Table A13 (cont): Definition of ‘Modern’ and ‘Traditional’ Processes 
Environmental Biotechnologies 
 
 
Notes:  
‘Modern’ biotech processes (for the purpose of this report) are represented in normal font, white 
background.  
‘Traditional’ biotech processes in italic, grey background. 
* indicates Statistics Canada category is probably correct but needs to be reviewed. 
 
 
 
 
 
 
 
 
 
 
 
 
SNZ Q 
No.
Process Definition in Biotechnology Survey 1998/99 Stat's 
Canada 
Categ'y
7.1 Bioaugmentation The process of increasing the efficiency of the naturally occurring 
microbial population to concentrate or accumulate specific com-pounds. 
This is usually achieved by adding nutrients, oxygen or water
none
7.2 Bio-reactors Enclosed containers in which micro-organisms are maintained under 
controlled conditions for the purpose of creating or destroying specific 
compounds
none
7.3 Biological Gas Cleaning The use of micro-organisms to break down or degrade hazardous 
substances in a gas stream into less hazardous or non-toxic substances
none
7.4 Bio-remediation The use of naturally occurring or genetically modified micro-organisms to 
breakdown or degrade hazardous substances into less hazardous or non-
toxic substances
1270
7.5 Phytoremediation The use of plants to treat or clean environmental pollution 1270
7.6 Other Environmental 
Environmental Biotechnologies: Biotechnologies used for pollution control
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Table A13 (cont): Definition of ‘Modern’ and ‘Traditional’ Processes 
Bioprocessing Based 
 
  
Notes:  
‘Modern’ biotech processes (for the purpose of this report) are represented in normal font, white 
background.  
‘Traditional’ biotech processes in italic, grey background. 
* indicates Statistics Canada category is probably correct but needs to be reviewed. 
SNZ Q 
No.
Process Definition in Biotechnology Survey 1998/99 Stat's 
Canada 
Categ'y
8.1 Cell Culture A population of cells grown for microbiological testing, cell culture 
development or in fermenters to study their biology or to manufacture 
products
1230
8.2 Tissue Culture A technique for growing cells from multi-cellular organisms in a artificial 
medium
1230
8.3 Embryo Culture A technique for growing embryos from multi-embryo organisms in an 
artificial medium
1230
8.4 Cell Manipulation Ability to grow and modify a range of cell types under laboratory 
conditions
1230
8.5 Tissue Manipulation Ability to grow and modify a range of tissue types under laboratory 
conditions
1230
8.6 Embryo Manipulation Ability to grow and modify a range of embryo types under laboratory 
conditions
1230
8.7 Fermentation Micro-organic process in which the metabolism of sugars for energy is 
accompanied by the formation of alcohol and/or lactic acid and solvents. 
Include processes such as wine, cheese and youghurt making, brewing, 
yeast production etc.
1250
8.8 Bioprocessing Production stages that include fermentation, recovery and purification 1250
8.9 Biotransformation Conversion of one chemical or material into another using a biological 
catalyst
1250
8.10 Bio-leaching Use of micro-organisms to leach metals from ore 1260
8.11 Bio-pulping The use of enzymes to degrade wood structures to produce pulp for paper 
making purposes
1260
8.12 Bio-bleaching The use of enzymes to bleach paper fibre 1260
8.13 Bio-desulphurisation The removal of organic or inorganic sulphur from coal by bacterial or soil 
micro-organisms
1260
8.14 Bio-pesticide manufacturing Biological pest control through the use of naturally occurring microbes or 
bacteria
none
8.15 Extraction/Concentration/ 
Purification/Separation
The retrieval of a compound of interest from a raw material 1240
8.16 Biofiltration The treatment of sewage or industrial wastewaters using active biomass 
growing on a solid support
none
8.17 Bioindicators The use of organisms to indicate the status of an environment none
8.18 Micro Selected Breeding Using modern biotechnological tools to acelerate selection none
8.18 Natural Products Chemistry The study of a biological material or a biologically-derived material using 
analytic methods, normally being the isolation and identification of the 
novel chemicals within a biological material
1250
8.20 Microbio-inoculants Naturally occurring bacterial inoculates used to promote plant growth none
8.21 Somatic Embryo-genesis Propagation of genetically desirable plant and tree lineages by tissue 
culture methods
1230 *
8.22 Other Bioprocessing 
Bioprocessing Based: Processing of any natural material of biological origin
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